AlzChem Group (ACT) Q3 2026 earnings summary

Executive summary

• 9M 2026 sales rose 4.5% to €443.8m; EBITDA increased 8.1% to €93.2m and margin expanded to 21.0%.

• Specialty Chemicals led growth on strong nutrition and defense demand, offsetting weaker Basics & Intermediates results.

• FY 2026 guidance was reaffirmed at ~€600m sales and ~€126m EBITDA, with ~21.0% EBITDA margin expected.

Financial highlights

• Q3 sales increased 1.9% to €139.9m; EBITDA declined 3.5% to €28.7m and margin eased to 20.5% from 21.7%.

• 9M EBIT was €69.4m versus €66.5m; period result rose to €48.4m from €46.8m.

• 9M diluted EPS rose to €4.77 from €4.62; Q3 EPS fell to €1.34 from €1.61.

• 9M operating cash flow was €97.4m; investing outflow reached €117.6m, leaving free cash flow at -€20.2m.

• Customer grants contributed €11.4m to 9M operating cash flow, versus €55.5m in 9M 2025.

Outlook and guidance

• FY 2026 forecast reaffirmed: sales ~€600m (+7%), EBITDA ~€126m (+8%) and EBITDA margin ~21.0%.

• Organic growth is expected to come from Specialty Chemicals; Basics & Intermediates sales are expected slightly below 2025.

• First sales from expanded German guanidine nitrate and nitroguanidine capacity are expected in Q4 2026; creatine facility commissioning is scheduled from H2 2027.

• Guidance assumes energy and raw-material cost increases are passed through or offset; further Iran-conflict and long-term supply-chain effects are excluded.

• The ~€120m creatine capacity expansion remains on plan, with commissioning in phases from H2 2027.